X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Proceeds from the financing will advance Obsidian’s lead-engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer.
Lead Product(s): OBX-115
Therapeutic Area: Oncology Product Name: OBX-115
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Wellington Management
Deal Size: $160.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing April 03, 2024
Details:
OBX-115 is a cell and gene therapy drug candidate, which is being evaluated in combination with for the treatment of patients with advanced or metastatic melanoma.
Lead Product(s): OBX-115,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: OBX-115
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
The observed in vitro and in vivo persistence of cytoTIL15 TILs, in the absence of IL2, to superior in vivo anti-tumor efficacy in PDX models supports the potential for increased efficacy of cytoTIL15 therapy over conventional TIL therapy in solid tumor malignancies.
Lead Product(s): CytoTIL15
Therapeutic Area: Oncology Product Name: CytoTIL15
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Details:
The abstract for the poster describes how Obsidian’s cytoTIL15 product demonstrates enhanced in vitro potency and phenotype and in vivo persistence in the absence of IL-2, paving the way for more durable efficacy and improved safety in patients with solid tumor malignancies.
Lead Product(s): CytoTIL15
Therapeutic Area: Oncology Product Name: CytoTIL15
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
This multi-year strategic research collaboration leverages Obsidian’s proprietary cytoDRiVE® platform to discover controllable genetic therapies to treat serious diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Vertex
Deal Size: $1,300.0 million Upfront Cash: $75.0 million
Deal Type: Collaboration April 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
